Purpose: The aim of this study was to assess the impact of missing death data on survival analyses conducted in an oncology EHR-derived database.
| INTRODUCTION
Real-world evidence (RWE) generated from real-world data (RWD), including data derived from electronic health records (EHRs), is increasingly important for pharmacoepidemiological research. 1 These data provide opportunities for deriving clinical insights and serve to complement findings from clinical trials. In order to synthesize RWD into high-quality RWE, outcomes data are needed, and mortality-based outcomes (eg, overall survival [OS] and progression-free survival [PFS] ) are particularly important for many disease areas, including oncology.
Mortality-based RWD have multiple applications, both for standalone research studies and to complement traditional trials.
These include describing the survival outcomes of a single group of patients (eg, median OS) and comparative effectiveness research (CER), where outcomes from two or more groups of patients are compared against each other, typically expressed as hazard ratios (HRs).
Although these analyses could involve multiple data sources, a strength of RWE is that datasets are often large enough that these questions can be addressed within a single, harmonized database, which leverages consistent data-generating mechanisms across groups. Another emerging application for RWE is to serve as an external control arm for single-arm trials, where every patient receives the experimental treatment. 1 Although a control arm is not built into the study, researchers often wish to make comparisons between the experimental treatment and contemporaneous control treatments external to the trial. Therefore, this application faces the additional challenge that outcomes data are compared across multiple data sources, conflating any differences in treatment effect (eg, HR estimates) with differences in underlying data. Lastly, real-world mortality data can be used for trial planning purposes, where estimates from real-world populations could be used for either power calculations or planning the time needed to accrue a number of events.
Due to its critical role in identifying a survival benefit associated with a treatment regimen, the quality of the underlying mortality data used in RWE studies is of salient interest. In EHR-derived databases, mortality data are collected in a structured format as part of routine clinical care. However, researchers often must augment incomplete EHR mortality data with other sources, such as national death indices and commercial sources. 2 Ideally, the quality of the data source will have benchmarks against a gold standard. While rules can be applied to address specificity and date agreement by flagging potential false positives or improbable dates, there are limited ways to address imperfect sensitivity short of obtaining additional data. Thus, missing deaths are of paramount interest when describing the quality of EHR-derived mortality data.
Once mortality quality benchmarks are in place, researchers are often faced with the question of how good is good enough? There are currently no universally accepted minimum standards or consensus with regard to an acceptable level of mortality completeness; rather, the right standard likely depends on the particular analysis. 3, 4 Even if deaths are missing completely at random, incomplete mortality data results in absolute estimates of OS, such as median OS (mOS), being biased upward. 5, 6 If missing deaths are equally distributed between comparator arms, the impact on relative risk estimates, such as HRs, should be minimal; however, this assumption may not hold in applications such as external control arms where the experimental and control arms are drawn from different data sources. Beyond these hypothetical implications, how do missing deaths impact findings in applications of interest to researchers utilizing RWE?
We sought to answer these questions using an oncology EHRderived data source, where a recent study reported greater than 90% mortality sensitivity in advanced non-small cell lung cancer (aNSCLC)
patients. 2 We tested the impact of missing deaths in the EHR-derived data source-both at the high sensitivity levels observed in practice and artificially reduced for illustrative purposes-by comparing the output of descriptive analyses, CER, and external control arms to those obtained using a gold standard data source. Thus, we aimed not only to understand the impact of missing deaths in the EHR-derived data source utilized here but also, more broadly, to understand what levels of mortality sensitivity are high enough quality to minimize impact on analytic results.
| METHODS

| Study overview
The purpose of this retrospective observational study was to evaluate the impact of missing deaths on survival analyses from an EHRderived RWE database in patients diagnosed with aNSCLC, as compared with a gold standard data source. Institutional Review Board and National Center for Health Statistics approval of the study protocol was obtained prior to study conduct. Informed consent was waived as this was a non-interventional study using routinely collected data. Flatiron Health standard methodology for data security and patient privacy was implemented. the EHR-derived data or in the gold standard ( Figure 1 , "Classification by Gold Standard").
| Sampling methods
In addition to the classification described above corresponding to the empirically observed sensitivity in the EHR-derived data source (90.6% as compared with the gold standard 2 ), lower sensitivity datasets were generated through simulation ( 
| Statistical analysis
Descriptive statistics on the demographic and clinical characteristics of the cohort were calculated, stratified by the classification of the EHRderived mortality variable against the gold standard. Among patients with missing EHR-derived death data (cell C), the last confirmed structured activity date (ie, their last visit or administration in the EHR) was compared with the death date in the gold standard data source, and the distribution of differences between dates was visually examined.
Three sets of comparison groups were selected to examine the impact of missing deaths and were chosen based on known prognostic and/or predictive properties to allow for a number of expected effect sizes. [9] [10] [11] [12] [13] [14] For the first comparison, we selected treatments commonly 
KEY POINTS
• The impact of missing death data on survival analyses and estimates of overall survival is small when mortality capture sensitivity is high (eg, approximately 90% or more).
• The magnitude of bias is increased and, at times, substantial, with lower mortality sensitivities in the 60% to 70% range.
• The direction of the effect estimation may also change with lower mortality sensitivities in the 60% to 70%
range.
• Electronic health records mortality data with high sensitivity limit the potential for missing deaths to bias OS estimates allowing valid inferences to be drawn. When comparing patients with missing death dates (ie, false negatives, cell C) to other patients, the group with missing death dates had a lower proportion of white patients and a higher proportion of black patients; more patients residing in the western region with less in both the northeast and midwestern regions; a higher proportion of patients with no treatment recorded in the EHR; and a shorter median follow-up time recorded in the EHR. Differences in the race distribution could reflect reporting variations across race while it would be expected that patients with missing death dates would also be associated with both less treatment (eg, reflecting patients with incomplete EHR records or patients treated outside of the EHR) and shorter follow-up time due to mortality. 
| Impact of missing deaths on absolute survival estimates
An upward bias in mOS of approximately 0.5 months was observed in EHR-derived death data for patients treated with platinum agents in first-line compared with the benchmark ( 
| Impact on CER analyses
When HRs were examined, a lack of systematic bias between exposure groups was observed, including within the two simulated cohorts, with only small differences seen in the HRs for the EHR-derived death data across all three comparisons relative to HRs obtained for the gold standard death data ( Figure 4A-C) . Despite large observed differences in mOS between the simulated cohorts and the gold standard cohort, comparisons of relative risk such as HRs were largely unaffected by missing death data. 
| Impact on external control arm analyses
Given the systematic differences in mortality capture of the exposure groups artificially introduced in the external control arm analyses, the impact of missing deaths on these analyses was much more pronounced ( Figure 5A -C) than in analyses performed entirely within the EHR-derived database (ie, measures of absolute risk or CER analyses). The impact ranged from modest differences in the EHR-derived 
| DISCUSSION
RWE sources, including EHR-derived datasets, are valuable analytic platforms for conducting clinical research. 1 Mortality serves as the primary outcome in many analyses across disease areas and particularly for oncology. However, it is often incomplete because of imperfect data collection systems, workflows not designed to capture mortality data, and patients lost to follow up. 5, 15, 16 The purpose of this study was to examine the potential impact of missing death data in an EHRderived oncology data source, which is of critical importance to establishing a research-grade EHR-derived database and should provide guidance with respect to an acceptable level of completeness. [16] [17] [18] In CER analyses, there was little to no impact on the estimated
HRs as compared with the gold standard data source, regardless of the sensitivity level. This result suggests that conclusions from CER analyses where both comparators originate from the same highsensitivity RWE data source can be interpreted with confidence, even for the lower sensitivity data sources simulated here. However, data sources with missing deaths consistently overestimated mOS, as compared with the gold standard data source. This impact was modest for the sensitivity observed in the EHR-derived database (2.5%-8.1% bias) but increased when sensitivity was artificially lowered (eg, up to 53.2%
bias in the simulated cohort with 63.4% sensitivity). These findings One key opportunity for RWE in drug development is to serve as an external control for a single-arm clinical trial. 1 With the EHRs current mortality sensitivity of greater than 90%, creating differential sensitivity in the context of external control arm analyses resulted only in small differences in estimated HRs and would lead to conservative conclusions and biasing against the experimental arm (eg, absolute change in HR of less than 0.05 towards the null) with corresponding small increases in the probability of type II errors. In drug development, bias in the direction of the null is preferable to an enhanced risk of a type I error.
Also, decisions on molecule phase advancement within drug development (e.g., from single-arm phases 1b to 3 randomized trials) generally would not change based on a 0.05 absolute difference in a phase 1b HR. Conversely, when the sensitivity was lowered, the impact was far more pronounced and much more likely to alter decision making.
Other studies have examined the impact of missing deaths with little evidence to suggest meaningful estimation bias when the mortality outcome is reasonably well captured (ie, 85%-90% sensitivity). 4, 15 Some studies have observed systematic differences in comparative analyses likely attributable in part to informative censoring in settings where exposures are related differentially to the mortality outcome. 16, 19 Given the absence of any meaningful estimation bias when sensitivity is greater than 90%, why was it important to conduct this study? It was clear from the simulated analyses at lower sensitivities that the impact of missing endpoints such as mortality can have a major effect on analyses, in particular on estimates of absolute risk.
Although there are a number of thresholds that have been discussed with respect to levels of missing outcomes in EHRs, there is a dearth of empirical support. 3, 4 Understanding the impact of missing deaths in EHRs is essential to instilling confidence in this rapidly evolving source of clinical evidence. In doing so, researchers will ensure a level of scientific rigor that will allow for sensible use of EHR-derived data for clinical research as an adjunct to the gold standard randomized clinical trials.
There are a number of study limitations that should be considered when evaluating the findings. First, this study leveraged data from community-based oncology clinics in the United States, and patterns of missing data may be different in academic centers or in other countries. This analysis assumes that the NDI is a gold standard for mortality, yet any database at this scale is unlikely to capture every death. 20 Second, this study did not consider the mechanism for missing deaths.
Although we observed little impact on the examples studied here with high-sensitivity mortality data, regardless of mechanism, further work is needed to describe the presence and degree of informative censoring in these data and understand its impact. Third, despite the minimal impact on most conclusions observed in aNSCLC, it is unclear how this will expand to other cancer types with longer mOS. Lastly, although FIGURE 5 Impact of missing deaths on analyses that use the EHR-derived data as an external control arm: current mortality sensitivity vs simulated sensitivities compared with gold standard benchmark. For the external control analyses, the experimental arm in all analyses is composed of the gold standard data, and the control arm is composed of the EHR-derived data only. For simulations 1 and 2, the same approach is taken where the experimental arms are composed of the gold standard data, and the control arms are composed of the EHR-derived data only (with their respective simulated lower sensitivities). Each analysis is in turn compared with an analysis conducted using the gold standard data only (solid red vertical line in Figure 5 represents the HR using the gold standard with dashed line representing its corresponding 95% CI) [Colour figure can be viewed at wileyonlinelibrary.com] the comparison groups were chosen to represent a range of common research questions, they are not exhaustive.
Strength of the study include the varying levels of mortality sensitivity and large sample size. Additionally, the study utilized a gold standard data source; in many examinations of missing data, a proxy for the complete data is never available for comparison. Finally, a variety of analytic use cases were examined, including the novel use of EHR-derived data as an external control.
Although modest bias was observed for absolute estimates and external control analyses when sensitivity was greater than 90%, the bias occurred in a consistent direction and would not likely impact study conclusions or decision making. However, mortality data with lower sensitivity allows for the possibility of more substantial bias to enter into analyses conducted using EHR-derived data. For analyses of mortality based on external controls, researchers should understand the level sensitivity of the data and consider the impact on bias. Using EHR-derived mortality data with high sensitivity mitigates the likelihood that analyses performed using the data will be subject to bias of any meaningful magnitude. In fact, based on the findings from the current study, achieving perfect mortality capture (100% sensitivity) in an EHR-derived database would not result in meaningful gains in terms of a researcher's ability to draw conclusions from the data as compared with the greater than 90% sensitivity observed in this dataset.
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